Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Health Care Sector · Hartford

The Hartford Healthcare Fund Class R3 (HGHRX)

Ticker HGHRX · · Holdings as of Jul 31, 2026

Expense ratio
1.66%$166/yr per $10k
Net assets
$772.2Mall share classes
Holdings
80

Bottom line

Is HGHRX a good fund? The bottom line

HGHRX is the Class R3 share class of The Hartford Healthcare Fund, a managed health care sector mutual fund from Hartford.

Its expense ratio is 1.66% — about $166 a year on every $10,000 invested, more expensive than 86% of health care sector funds we track.

With $772 million in net assets and 80 holdings, its largest position is Eli Lilly & Co (12.0%) and the top 10 make up 47.7% of the portfolio.

The closest lower-cost alternative we found is XLV (0.08%, 72% top-holdings overlap).

What stands out

  • No front-end sales load

What to watch

  • Expensive for its category (1.66%)
  • 12b-1 marketing fee of 0.5% a year

Updated Nov 19, 2026

What HGHRX invests in

The Fund seeks long-term capital appreciation.

Under normal circumstances, the Fund invests at least 80% of its assets in the equity securities of health care-related companies worldwide as selected by the sub-adviser, Wellington Management Company LLP (Wellington Management). Wellington Managements investment process focuses on stock selection through fundamental analysis. The Fund takes a broad approach to investing in the health care sector. The Fund may invest in health-related companies, including companies in the pharmaceuticals, biotechnology, medical delivery, medical products, medical services, managed health care, health information services and emerging health-related subsectors. The Funds assets will be allocated across the major subsectors of the health care sector, with some representation typically maintained in each major subsector. The Fund will normally invest at least 25% of its total assets, in the aggregate, in…

From the fund's prospectus (filed Feb 26, 2026).

What HGHRX costs

On a $10,000 investment, HGHRX's 1.66% expense ratio costs about $166 a year. The prospectus estimates $1,965 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.

See the full HGHRX fee table →

HGHRX top 10 holdings

#Holding% of fund
1Eli Lilly & Co12.03%
2Johnson & Johnson6.75%
3Merck & Co Inc6.00%
4UnitedHealth Group Inc4.74%
5AbbVie Inc4.21%
6Elevance Health Inc3.00%
7Intuitive Surgical Inc2.88%
8CVS Health Corp2.84%
9Vertex Pharmaceuticals Inc2.64%
10Danaher Corp2.57%

Source: SEC Form N-PORT, period ended Jul 31, 2026

The top 10 make up 47.7% of the fund. See all top 25 holdings and asset mix →

Alternatives to HGHRX

Closest equivalent at other fund companies
FamilyFundExpense ratioOverlap
SPDR (State Street)XLV State Street(R) Health Care Select…0.08%72% Compare
FidelityFHLC Fidelity MSCI Health Care Index ETF0.084%72% Compare
VanguardVGHCX Vanguard Health Care Fund0.33%77% Compare
iSharesIYH iShares U.S. Healthcare ETF0.37%68% Compare
J.P. MorganJDOC JPMorgan Healthcare Leaders ETF0.65%61% Compare
SchwabSWHFX Schwab Health Care Fund0.8%65% Compare

More funds like HGHRX →

HGHRX FAQ

What is the expense ratio of HGHRX?
HGHRX's expense ratio is 1.66%, which works out to about $166 a year for every $10,000 invested. The prospectus estimates total costs of $1,965 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is HGHRX a good investment?
It depends on your goals, but the data points to: no front-end sales load; expensive for its category (1.66%); 12b-1 marketing fee of 0.5% a year. This is general information, not personalized advice.
What does HGHRX hold?
HGHRX's largest holdings are Eli Lilly & Co (12.0%), Johnson & Johnson (6.7%), Merck & Co Inc (6.0%), UnitedHealth Group Inc (4.7%), AbbVie Inc (4.2%). It holds 80 positions in total as of Jul 31, 2026 (SEC Form N-PORT).
Does HGHRX have a sales load?
No. HGHRX has no front-end sales charge.
What is a cheaper alternative to HGHRX?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) overlaps about 72% with HGHRX and charges 0.08%.
Who manages HGHRX?
HGHRX is offered by Hartford through Hartford Mutual Funds, Inc.